UBS analyst Dan Leonard raised the firm’s price target on West Pharmaceutical (WST) to $355 from $320 and keeps a Buy rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical price target raised to $345 from $305 at Deutsche Bank
- West Pharmaceutical Services Reports Strong Q3 2025 Results
- West Pharmaceutical Services’ Earnings Call: Optimistic Growth Amid Challenges
- West Pharmaceutical price target raised to $390 from $350 at Evercore ISI
- Early notable gainers among liquid option names on October 23rd